Immunogenicity of an Inactivated Hepatitis A Vaccine
Authors: Maria H. Sjogren, Charles H. Hoke, Leonard N. Binn, Kenneth H. Eckels, Doria R. Dubois, Lionel Lyde, Amy Tsuchida, Stanley Oaks, Ruth Marchwicki, Wayne Lednar, Robert Chloupek, John Ticehurst, William H. Bancroft
Journal: Annals of Internal Medicine (1991)

Brief Report15 March 1991Immunogenicity of an Inactivated Hepatitis A VaccineMaria H. Sjogren, MD, MPH, Charles H. Hoke, MD, Leonard N. Binn, PhD, Kenneth H. Eckels, PhD, Doria R. Dubois, PhD, Lionel Lyde, Amy Tsuchida, MD, Stanley Oaks Jr., PhD, Ruth Marchwicki, BS, Wayne Lednar, MD, PhD, Robert Chloupek, MD, John Ticehurst, MD, William H. Bancroft, MDMaria H. Sjogren, MD, MPHSearch for more papers by this author, Charles H. Hoke, MDSearch for more papers by this author, Leonard N. Binn, PhDSearch for more papers by this author, Kenneth H. Eckels, PhDSearch for more papers by this author, Doria R. Dubois, PhDSearch for more papers by this author, Lionel LydeSearch for more papers by this author, Amy Tsuchida, MDSearch for more papers by this author, Stanley Oaks Jr., PhDSearch for more papers by this author, Ruth Marchwicki, BSSearch for more papers by this author, Wayne Lednar, MD, PhDSearch for more papers by this author, Robert Chloupek, MDSearch for more papers by this author, John Ticehurst, MDSearch for more papers by this author, William H. Bancroft, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-6-470 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough hepatitis A is a disease without chronic sequelae, it is associated with serious morbidity in adults. An inactivated hepatitis A vaccine prepared at the Walter Reed Army Institute of Research was observed to successfully immunize owl monkeys (1). In a preliminary study, this vaccine was given to eight men, all of whom developed neutralizing antibody to hepatitis A virus (anti-HAV) (2). The present study was designed to confirm the vaccine's immunogenicity, to obtain additional evidence of vaccine safety, and to establish a practical dosing schedule.MethodsForty-two male volunteers, 18 to 50 years of age, were enrolled from among...References1. BinnBancroftEckels LWK. Inactivated hepatitis A virus vaccine produced in human diploid MRC-5 cells. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, Inc; 1988:91-3. Google Scholar2. SjogrenEckelsBinn MKL. Safety and immunogenicity of an inactivated hepatitis A vaccine. In Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, Inc; 1988:94-6. Google Scholar3. LemonBinn SL. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis. 1983;148:1033-9. CrossrefMedlineGoogle Scholar4. Hepatitis Surveillance Report No. 52. Atlanta, Georgia: Centers for Disease Control; 1989:10. Google Scholar5. StapletonJansenLemon JRS. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology. 1985;89:637-42. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From Walter Reed Army Institute of Research, Washington, D.C.; Fort Lewis, Washington; and United States Army Medical Materiel Development Activity, Frederick, Maryland. For current author addresses, see end of text. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEpidemiology of Hepatitis A: Past and Current TrendsHistory of the Discovery of Hepatitis A VirusEnterically Transmitted Viral HepatitisA model international partnership for community-based research on vaccine-preventable diseases: The Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU)Enterically Transmitted Viral Hepatitis: Hepatitis A and Hepatitis EHepatitis AThe European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countriesRole of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseasesDiagnosis of Hepatitis A Virus Infection: a Molecular ApproachHepatitis A Transmitted by FoodHepatite AHepatitis A vaccineTravel-Related VaccinesHepatitis A: Old and NewCURRENT UPDATE OF PEDIATRIC HEPATITIS VACCINE USEHepatitis A VaccinesHepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimensHepatitis A ProphylaxisViral infections of the liverImmunogenicity of inactivated hepatitis A vaccine in childrenThe success of hepatitis A vaccineSimultaneous active and passive immunization against hepatitis A studied in a population of travellersHepatitis A—New information on an old virusHepatitis A virus: Current concepts of the molecular virology, immunobiology and approaches to vaccine developmentIMMUNIZATIONSSafety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis AVaccination against hepatitis A: Control 3 years after the first vaccinationA single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeksHepatitis A in the US Army: epidemiology and vaccine developmentLaboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccineThe Main Five Types of Viral Hepatitis: An Alphabetical UpdateThe hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles 15 March 1991Volume 114, Issue 6Page: 470-471KeywordsHepatitis AHepatitis A virusMorbiditySafetySafety studiesVaccines Issue Published: 15 March 1991 PDF downloadLoading ...